Published in Annu Rev Immunol on January 01, 2007
Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology (2008) 2.91
Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. J Clin Invest (2010) 2.68
PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest (2009) 2.26
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology (2011) 2.13
Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest (2008) 2.08
A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology (2011) 2.06
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A (2012) 2.05
Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol (2008) 1.90
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood (2007) 1.72
Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production. Mol Cell (2012) 1.61
A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum (2012) 1.60
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol (2010) 1.55
Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest (2009) 1.46
Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology (2009) 1.46
Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology (2009) 1.40
Hepatitis C virus infection and apoptosis. World J Gastroenterol (2007) 1.36
Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. Hepatology (2012) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
The interferon inducible gene: Viperin. J Interferon Cytokine Res (2010) 1.33
Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol (2010) 1.31
Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A. PLoS One (2010) 1.29
Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv (2015) 1.25
In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology (2011) 1.23
Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett (2010) 1.22
Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway. J Biol Chem (2011) 1.22
Immune defence, parasite evasion strategies and their relevance for 'macroscopic phenomena' such as virulence. Philos Trans R Soc Lond B Biol Sci (2009) 1.20
HCV drug discovery aimed at viral eradication. J Viral Hepat (2009) 1.19
Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. J Hepatol (2010) 1.15
Hepatitis C virus infection induces the beta interferon signaling pathway in immortalized human hepatocytes. J Virol (2007) 1.12
Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput Biol (2013) 1.12
Innate immune responses in hepatitis C virus infection. Semin Immunopathol (2012) 1.06
Virus-specific host miRNAs: antiviral defenses or promoters of persistent infection? Trends Immunol (2008) 1.04
KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infection. PLoS Pathog (2011) 1.02
Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients. J Clin Immunol (2013) 1.02
The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect (2011) 1.01
T-cell responses in hepatitis B and C virus infection: similarities and differences. Emerg Microbes Infect (2013) 1.00
Regulatory T cells in viral hepatitis. World J Gastroenterol (2007) 0.99
Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses (2010) 0.98
M. tuberculosis T Cell Epitope Analysis Reveals Paucity of Antigenic Variation and Identifies Rare Variable TB Antigens. Cell Host Microbe (2015) 0.96
Hepatitis C virus promotes T-helper (Th)17 responses through thymic stromal lymphopoietin production by infected hepatocytes. Hepatology (2013) 0.95
Protective immunity against hepatitis C: many shades of gray. Front Immunol (2014) 0.94
Hepatitis C virus infection and mixed cryoglobulinemia. Clin Dev Immunol (2012) 0.94
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines. Virology (2013) 0.93
Targeting host factors: a novel rationale for the management of hepatitis C virus. World J Gastroenterol (2009) 0.93
Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci (2009) 0.92
T cell sensitivity and the outcome of viral infection. Clin Exp Immunol (2009) 0.92
Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans. J Virol (2011) 0.92
The evolutionary dynamics of a rapidly mutating virus within and between hosts: the case of hepatitis C virus. PLoS Comput Biol (2009) 0.91
Characterization of human antiviral adaptive immune responses during hepatotropic virus infection in HLA-transgenic human immune system mice. J Immunol (2013) 0.91
Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J Biol Chem (2012) 0.91
The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol (2014) 0.89
Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology (2014) 0.89
The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol (2010) 0.89
An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol (2013) 0.87
Immunization with a recombinant vaccinia virus that encodes nonstructural proteins of the hepatitis C virus suppresses viral protein levels in mouse liver. PLoS One (2012) 0.87
Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. J Virol (2014) 0.87
Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol (2014) 0.87
Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection. J Virol (2015) 0.86
Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol (2016) 0.86
Adaptive immune response during hepatitis C virus infection. World J Gastroenterol (2014) 0.85
Patients with chronic hepatitis C express a high percentage of CD4(+)CXCR5(+) T follicular helper cells. J Gastroenterol (2012) 0.84
Role of host genetic factors in the outcome of hepatitis C virus infection. Viruses (2009) 0.84
A disulfide-bonded dimer of the core protein of hepatitis C virus is important for virus-like particle production. J Virol (2010) 0.84
Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy. PLoS One (2012) 0.83
Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor. Antimicrob Agents Chemother (2013) 0.83
Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. Cell Mol Immunol (2015) 0.82
Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles. PLoS One (2013) 0.82
T lymphocytes from chronic HCV-infected patients are primed for activation-induced apoptosis and express unique pro-apoptotic gene signature. PLoS One (2013) 0.81
Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes. Virol J (2011) 0.81
Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C. J Viral Hepat (2013) 0.81
Acute hepatitis C in an HIV-infected patient: a case report and review of literature. J Gen Intern Med (2012) 0.81
T-cell dysfunction and inhibitory receptors in hepatitis C virus infection. Immune Netw (2010) 0.80
Molecular and contextual markers of hepatitis C virus and drug abuse. Mol Diagn Ther (2009) 0.80
IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test. Immunogenetics (2013) 0.80
The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion. J Immunol (2014) 0.80
Characterization of antigenic variants of hepatitis C virus in immune evasion. Virol J (2011) 0.79
Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice. Hepat Mon (2014) 0.79
Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection. Gut (2015) 0.78
Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo. PLoS One (2012) 0.78
Robust and sustained immune activation in human Ebola virus infection. Proc Natl Acad Sci U S A (2015) 0.78
Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular Carcinoma. Korean J Physiol Pharmacol (2013) 0.78
LIGHT induces distinct signals to clear an AAV-expressed persistent antigen in the mouse liver and to induce liver inflammation. PLoS One (2010) 0.78
Advancement in the development of models for hepatitis C research. J Biomed Biotechnol (2012) 0.78
Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World J Hepatol (2015) 0.78
Immunological changes in different patient populations with chronic hepatitis C virus infection. World J Gastroenterol (2016) 0.77
Natural killer cell function and dysfunction in hepatitis C virus infection. Biomed Res Int (2014) 0.77
Primary, post-primary and non-specific immunoglobulin M responses in HCV infection. Antivir Ther (2012) 0.77
A systematic analysis of a broadly neutralizing antibody AR3C epitopes on Hepatitis C virus E2 envelope glycoprotein and their cross-reactivity. BMC Med Genomics (2015) 0.77
Innate and Adaptive Immune Responses in Chronic HCV infection. Curr Drug Targets (2015) 0.77
IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort. BMC Res Notes (2014) 0.77
Anti-apoptotic effect of HCV core gene of genotype 3a in Huh-7 cell line. Virol J (2011) 0.77
Cross-linking of CD81 by HCV-E2 protein inhibits human intrahepatic plasmacytoid dendritic cells response to CpG-ODN. Cell Immunol (2013) 0.77
Contradictory immune response in post liver transplantation hepatitis B and C. Int J Inflam (2014) 0.76
Natural killer cells in hepatitis C: Current progress. World J Gastroenterol (2016) 0.76
Role of T cell death in maintaining immune tolerance during persistent viral hepatitis. World J Gastroenterol (2013) 0.76
Adaptive immunity to hepatitis C virus. Viruses (2009) 0.75
Enhancement of humoral immunity in mice by coupling pUCpGs10 and aluminium to the HCV recombinant immunogen. Virol J (2011) 0.75
Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy. J Clin Transl Hepatol (2016) 0.75
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
A diverse range of gene products are effectors of the type I interferon antiviral response. Nature (2011) 12.86
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Suppression of inflammation by a synthetic histone mimic. Nature (2010) 8.80
Replication of hepatitis C virus. Nat Rev Microbiol (2007) 8.31
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 6.16
Unravelling hepatitis C virus replication from genome to function. Nature (2005) 5.25
HCV persistence and immune evasion in the absence of memory T cell help. Science (2003) 5.23
Molecular biology of flaviviruses. Adv Virus Res (2003) 4.39
Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol (2007) 4.28
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology (2014) 4.15
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84
Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature (2005) 3.83
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 3.47
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol (2010) 3.44
Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol (2011) 3.44
Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol (2004) 3.39
Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature (2013) 3.39
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci U S A (2002) 3.21
Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J Virol (2003) 3.19
The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem (2004) 3.15
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J Virol (2002) 3.07
Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology (2008) 2.91
Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A (2004) 2.77
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol (2009) 2.68
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63
Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature (2006) 2.58
Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 2.58
Roles of nonstructural protein nsP2 and Alpha/Beta interferons in determining the outcome of Sindbis virus infection. J Virol (2002) 2.55
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49
Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog (2010) 2.48
Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol (2007) 2.45
Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci U S A (2010) 2.44
euHCVdb: the European hepatitis C virus database. Nucleic Acids Res (2006) 2.41
MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature (2013) 2.40
Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology (2004) 2.37
A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol (2004) 2.36
Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol (2002) 2.31
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med (2009) 2.26
A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J Gen Virol (2003) 2.25
Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A (2012) 2.20
Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol (2003) 2.20
Characterization of a canine homolog of hepatitis C virus. Proc Natl Acad Sci U S A (2011) 2.14
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology (2011) 2.13
Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hepatology (2015) 2.11
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology (2011) 2.06
Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science (2012) 2.06
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A (2012) 2.05
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04
Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A (2004) 2.04
Tracking and elucidating alphavirus-host protein interactions. J Biol Chem (2006) 2.01
An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J Virol (2004) 1.99
Three conformational snapshots of the hepatitis C virus NS3 helicase reveal a ratchet translocation mechanism. Proc Natl Acad Sci U S A (2009) 1.94
Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol (2003) 1.93
Hepatitis C virus entry. J Biol Chem (2007) 1.91
Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol (2002) 1.87
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol (2009) 1.87
HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A (2013) 1.85
PKR-dependent and -independent mechanisms are involved in translational shutoff during Sindbis virus infection. J Virol (2004) 1.81
Serology-enabled discovery of genetically diverse hepaciviruses in a new host. J Virol (2012) 1.80
Uncleaved NS2-3 is required for production of infectious bovine viral diarrhea virus. J Virol (2004) 1.79
Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology (2006) 1.75
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes. PLoS Pathog (2009) 1.73
Alanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus. J Virol (2007) 1.73
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood (2007) 1.72
Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med (2005) 1.71
Superinfection exclusion in cells infected with hepatitis C virus. J Virol (2007) 1.71
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut (2014) 1.70
The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol (2013) 1.69
A dynamic view of hepatitis C virus replication complexes. J Virol (2008) 1.66
Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest (2006) 1.66
Evidence for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad Sci U S A (2007) 1.64
Studying hepatitis C virus: making the best of a bad virus. J Virol (2007) 1.62
3' RNA elements in hepatitis C virus replication: kissing partners and long poly(U). J Virol (2007) 1.62
Identification of rodent homologs of hepatitis C virus and pegiviruses. MBio (2013) 1.61
Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol (2002) 1.61
Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis. Nat Rev Microbiol (2008) 1.60
Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro. Proc Natl Acad Sci U S A (2012) 1.48
Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology (2005) 1.47
Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J Exp Med (2005) 1.46
Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology (2011) 1.42
Host factors associated with the Sindbis virus RNA-dependent RNA polymerase: role for G3BP1 and G3BP2 in virus replication. J Virol (2010) 1.38
Hepatitis C virus RNA synthesis in a cell-free system isolated from replicon-containing hepatoma cells. J Virol (2003) 1.36
Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J Exp Med (2012) 1.36
Dual mechanisms of pestiviral superinfection exclusion at entry and RNA replication. J Virol (2005) 1.35